• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：雌激素受体α/催乳素受体双侧串扰促进催乳素瘤对溴隐亭的耐药性：勘误

Erratum: Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum.

作者信息

Xiao Zhengzheng, Yang Xiaoli, Zhang Kun, Liu Zebin, Shao Zheng, Song Chaojun, Wang Xiaobin, Li Zhengwei

机构信息

Department of Henan Key Laboratory of Cancer Epigenetics; Cancer Institute, Department of Neurosurgery, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003.

Department of General Practice, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003.

出版信息

Int J Med Sci. 2022 May 3;19(5):831-832. doi: 10.7150/ijms.71659. eCollection 2022.

DOI:10.7150/ijms.71659
PMID:35693748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9149644/
Abstract

[This corrects the article DOI: 10.7150/ijms.51176.].

摘要

[本文更正了文章的数字对象标识符：10.7150/ijms.51176。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907e/9149644/9a965dfb61b6/ijmsv19p0831g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907e/9149644/fbad30f67ebb/ijmsv19p0831g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907e/9149644/9a965dfb61b6/ijmsv19p0831g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907e/9149644/fbad30f67ebb/ijmsv19p0831g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907e/9149644/9a965dfb61b6/ijmsv19p0831g002.jpg

相似文献

1
Erratum: Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum.勘误：雌激素受体α/催乳素受体双侧串扰促进催乳素瘤对溴隐亭的耐药性：勘误
Int J Med Sci. 2022 May 3;19(5):831-832. doi: 10.7150/ijms.71659. eCollection 2022.
2
Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.雌激素受体α/催乳素受体双向串扰促进催乳素瘤对溴隐亭的耐药性。
Int J Med Sci. 2020 Oct 23;17(18):3174-3189. doi: 10.7150/ijms.51176. eCollection 2020.
3
Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.催乳素在雌激素诱导的大鼠垂体催乳素瘤中的超微结构定位。人类催乳素瘤的实验模型及溴隐亭的作用。
Acta Pathol Jpn. 1986 Aug;36(8):1131-7. doi: 10.1111/j.1440-1827.1986.tb02834.x.
4
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.丝裂原活化蛋白激酶 11/12/13/14（p38MAPK）蛋白在多巴胺激动剂抵抗性泌乳素瘤中的作用。
BMC Endocr Disord. 2021 Nov 23;21(1):235. doi: 10.1186/s12902-021-00900-9.
5
[Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis].[溴隐亭对雌激素诱导的大鼠催乳素瘤的抗肿瘤作用：通过体视学分析对分泌颗粒变化的特别参考]
No To Shinkei. 1987 Apr;39(4):347-54.
6
Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.溴隐亭抵抗性催乳素瘤中Gα亚基mRNA水平的改变。
J Neuroendocrinol. 1996 Oct;8(10):737-46. doi: 10.1046/j.1365-2826.1996.04902.x.
7
[Pathological changes of prolactinomas treated with bromocriptine].
No Shinkei Geka. 1982 Jun;10(6):619-27.
8
Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.两例卡麦角林抵抗性泌乳素瘤患者对溴隐亭的阳性泌乳素反应。
Endocr Pract. 2011 May-Jun;17(3):e55-8. doi: 10.4158/EP10369.CR.
9
The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.妊娠及溴隐亭治疗对催乳素瘤的长期影响——放射学研究的价值
Early Pregnancy. 1997 Dec;3(4):306-11.
10
Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.不孕女性的泌乳素瘤：溴隐亭治疗24个月前后的临床及内分泌特征
Med Arch. 2013;67(3):181-4. doi: 10.5455/medarh.2013.67.181-184.